HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021

Dec 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-12-22

Reporting Person: Dissanaike Sharmila (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-22	Common Stock	A	10452	$0.00	Acquired	16702	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-22	Stock Option (Right to Buy)	$9.81	A	20903	Acquired	2031-12-22	Common Stock (20903)	Direct

Footnotes

F1: The shares were granted as restricted stock units which vest in full on December 22, 2022.

F2: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.